{"id":"abciximab-reteplase-abciximab-placebo-abciximab","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Bleeding"},{"rate":"1-2","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Back pain"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1201584","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T18:28:37.800202","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abciximab binds irreversibly to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, abciximab prevents fibrinogen and von Willebrand factor from cross-linking platelets, thereby inhibiting platelet clumping. This mechanism is particularly effective in acute coronary syndromes and during percutaneous coronary intervention (PCI) to reduce thrombotic complications.","oneSentence":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:30.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction)"},{"name":"Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT00046228","phase":"PHASE3","title":"A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2002-08","conditions":"Myocardial Infarction","enrollment":2461}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abciximab; reteplase; abciximab placebo; abciximab","genericName":"Abciximab; reteplase; abciximab placebo; abciximab","companyName":"Centocor, Inc.","companyId":"centocor-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention (PCI) in patients at high risk for ischemic complications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}